Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  BOLSA DE VALORES DE SAO PAULO  >  Hypermarcas SA    HYPE3   BRHYPEACNOR0

End-of-day quote. End-of-day quote  - 09/28
27.86 BRL   --.--%
07/28 HYPERMARCAS SA : ex-dividend day for interim dividend
07/23 HYPERMARCAS : Notice to the Market - Audit Committee
06/28 HYPERMARCAS : Material Fact
News SummaryMost relevantAll newsSector news 

Hypermarcas SA : Brazil's Hypermarcas returns to profit as debt costs sink

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2012 | 04:03pm CEST

Hypermarcas SA, Brazil's largest diversified drugmaker, returned to profit in the third quarter as revenue grew slightly above expectations and debt-servicing and currency hedging costs tumbled from the year-earlier period.

The results were the latest showing that a year-long slowdown in the consumer goods industry is finally easing, with producers of cosmetics, generic drugs and household goods such as Hypermarcas likely to benefit most from Brazil's improving growth trends. Hypermarcas had lost money for two of the past three quarters.

Surging pharmaceutical sales and the integration of acquisitions helped the São Paulo-based producer of Engov hangover pills and Bozzano shaving cream post net income of 68.38 million reais ($33.4 million) in the third quarter, according to a securities filing late on Friday. The result compared with a loss of 190.5 million reais a year earlier.

Third-quarter profit beat the 53 million reais estimate in a Reuters poll of analysts. Management will discuss third-quarter earnings in a conference call with investors early on Monday.

Chief Executive Claudio Bergamo's efforts to streamline operations has restored profitability after a spree of acquisitions in the past four years boosted debt and made Hypermarcas too exposed to an economic slowdown. Bergamo picked pharmaceutical goods and beauty care as the firm's focus, shunning the slower-growing foods and household goods units.

In a separate statement released late on Friday, Management also set an estimate of earnings before interest, tax, depreciation of around 950 million reais for next year, up from guidance of at least 850 million reais in the indicator, known as EBITDA, for this year. EBITDA is a measure of a company's ability to generate profits from its core business.

Lower debt and stronger cash flow generation, coupled with a stable currency, helped Hypermarcas post a net financial shortfall of 54.9 million reais, compared with a deficit of 331.8 million reais a year earlier. The net financial result line is calculated by the difference between debt-servicing and currency hedging expenses and non-operating income, such as gains from financial investments.

Revenue jumped to 992.9 million reais from 832.8 million reais a year earlier, a gain of 19 percent on a year-on-year basis, the company said. Sales of pharmaceutical products, which accounted for about 54 percent of the company's net revenue in the quarter, soared 39 percent, while those of beauty care goods rose 2.2 percent on a year-on-year basis.

The Reuters poll had predicted revenue at 987 million reais for the third quarter.

EBITDA almost quadrupled to 226.6 million reais last quarter from 66.3 million reais in the third quarter of 2011. The EBITDA margin, or how much operating profit was generated from sales, soared to 23 percent from 7.9 percent a year earlier.

EBITDA was expected to come in at 209 million reais in the Reuters poll, below the number reported by the company.

Shares of Hypermarcas, which shed 2.1 percent on Friday and closed the session at 15.32 reais, are up 80 percent so far this year.

($1 = 2.05 Brazilian reais)

(Reporting by Guillermo Parra-Bernal and Vivian Pereira; Editing by Vicki Allen)

By Guillermo Parra-Bernal and Vivian Pereira

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on HYPERMARCAS SA
07/28 HYPERMARCAS SA : ex-dividend day for interim dividend
07/23 HYPERMARCAS : Notice to the Market - Audit Committee
06/28 HYPERMARCAS : Material Fact
05/03DJCoty Swings to a Loss Amid Acquisition Costs
05/03DJCoty Swings to a Loss Amid Acquisition Costs
05/03 HYPERMARCAS SA : ex-dividend day for annual dividend
04/15 HYPERMARCAS SA : ex-dividend day for annual dividend
02/27 HYPERMARCAS : Press Release - Oferta de Recompra de Bond - Adesão Antecipada
02/12 HYPERMARCAS : Press Release - Oferta de Recompra de Bond
02/10 RECKITT BENCKISER : RB) to Acquire Brazilian Condom and Lubricant Business of Hy..
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Coty acquires Brazilian beauty business
2015 Kimberly-Clark on the hunt for Brazilian diaper business
Financials ( BRL)
Sales 2016 3 298 M
EBIT 2016 1 104 M
Net income 2016 1 503 M
Finance 2016 1 140 M
Yield 2016 2,09%
P/E ratio 2016 13,68
P/E ratio 2017 18,87
EV / Sales 2016 4,99x
EV / Sales 2017 4,55x
Capitalization 17 614 M
More Financials
Duration : Period :
Hypermarcas SA Technical Analysis Chart | HYPE3 | BRHYPEACNOR0 | 4-Traders
Full-screen chart
Technical analysis trends HYPERMARCAS SA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 29,9  BRL
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Claudio Bergamo dos Santos Chief Executive Officer & Director
João Alves de Queiroz Filho Chairman
Carlos Roberto Scorsi Executive Director-Operations
Martim Prado Mattos Chief Financial Officer & Controller
Esteban Malpica Fomperosa Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results